CPRX - Company ID 0001369568
The table below shows CATALYST PHARMACEUTICALS, INC.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $588.99M | $491.73M | $398.20M | $214.20M | $140.83M | $119.07M |
| Cost of revenue | $87.25M | $68.84M | $51.97M | $34.39M | $21.88M | $17.04M |
| Gross profit | - | - | - | - | - | - |
| R&D | $12.71M | $12.65M | $93.15M | $19.79M | $16.94M | $16.50M |
CATALYST PHARMACEUTICALS, INC. reported annual revenue of $588.99M for fiscal year 2025. That is up 19.8% from $491.73M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $193.75M |
| $177.74M |
| $133.71M |
| $57.09M |
| $49.63M |
| $44.23M |
| Operating income | $257.78M | $195.12M | $86.81M | $101.84M | $52.38M | $41.30M |
| Income tax | $69.19M | $52.37M | $23.10M | $21.64M | $13.19M | -$33.09M |
| Net income | $214.33M | $163.89M | $71.41M | $83.08M | $39.48M | $74.98M |
| EPS (diluted) | $1.68 | $1.31 | $0.63 | $0.75 | $0.37 | $0.71 |